🚨 Residents & fellows, we need your input! 🚨 Fill out the fellowship application survey forms.gle/cFyS6JLmsgNhbc… to help shape future fellowship application processes. Attendings, please share with your residents to ensure we capture everyone's voice! 🙏🙏 #MedEd #Fellowship

Great study on Porokeratosis by Burak Tekin journals.lww.com/amjdermatopath…

Hi pathology friends! Consult: Thoracic tumor. Exactly all of the information available to us. TTF-1 and p40 negative. What’s next? 🤔 #NatPathPuzzler #PulmPath PPS

Hi all - so great to see all of your posts! We considered ALL of the differentials you mentioned. Submitted IHC included most suggested markers - only strong positive was keratin. So .. I withheld an area that provided a clue.. here it is now 🫧 =😉

1/ Yes - you got it!! This is a super tricky case of thoracic CHORDOMA! A few points below:

Journal of Diagnostic and Academic Pathology journals.lww.com/jdap/fulltext/…

I’m so excited to share this paper published in Arch Pathol Lab Med highlighting the importance of #Pathology Student Interest Groups—check it out! meridian.allenpress.com/aplm/article/d…

So much fun! Thank you all for coming, for bringing cases, and for the intellectually stimulating discussion! 🙏🏾

This will be very interesting and informative session!! Please sign-up if you’re interested in lung biomarker testing and or digital computational pathology!! Sinchita Roy MD PhD Sanjay Mukhopadhyay Matthew Cecchini MD PhD FRCPC

Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU American Thoracic Society (ATS)

FIBRONEER-IPF results now online at NEJM!!! Nerandomilast slowed FVC decline at 52 weeks: −114.7 ml (18 mg BID) vs −183.5 ml (placebo) Difference: +68.8 ml (p<0.001) Benefit seen with and without background antifibrotics. #ATS2025

Presented at #ATS2025: In the FIBRONEER-ILD phase 3 trial involving patients with progressive pulmonary fibrosis, treatment with nerandomilast led to a smaller decline in the forced vital capacity than placebo over a period of 52 weeks. Full trial results:

When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!! nejm.org/doi/full/10.10…

Spectrum of Fibrotic Lung Diseases. nejm.org/doi/full/10.10…

What a fantastic #pathCast session with Dr. C. Christofer Juhlin from Karolinska University on adrenal tumors! He covered everything from histology to molecular updates. YouTube: youtube.com/watch?v=dmEIUz… #Pathology #Adrenal #MedicalEducation #EndocrinePath #MedicalEducation #EndocrinePath

As CLDN18.2 assessment in tissues become increasingly common, important to keep in mind pre-analytical variables like antibody clone. The same tumor can show widely different CLDN18.2 staining pattern as shown in this #GastricCancer. TL;DR Ventana/Roche (clone 43-14A) way to go.

Happy July 1 🥳 The start of a new academic year! To all who are beginning, continuing, or completing this path: Your presence matters. Your learning matters. Let’s keep building the future of medicine, one slide, one case, one day at a time. Here’s to the new year. Let’s

Occasionally juxtaglomerular cell tumors may lack expression of SMA: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

An Illustrative Guide on How To Measure Breast Tumors With Different Proportions and Distributions of DCIS and Invasive Carcinoma.🔬

Please join us for this amazing multispecialty conference! JAN 2026 Faculty are top notch teachers, including Sean R Williamson MD and Raza Hoda MD clevelandclinicmeded.com/live/courses/p…